
© 2024 Edison Investment Research
Realtime | Geld | Brief | Zeit |
---|---|---|---|
5,090 | 5,215 | 05.04. | |
5,080 | 5,120 | 04.04. |
Zeit | Aktuelle Nachrichten | |
---|---|---|
Do | OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 | |
Do | OSE Immunotherapeutics - Primed for value appreciation | |
26.03. | OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | |
12.03. | OSE Immunotherapeutics - Tedopi shows promise in pancreatic cancer | |
11.03. | OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi) in Advanced Pancreatic Cancer |